The safety profile of drotrecogin alfa (activated) by Fumagalli, Roberto & Mignini, Mariano A
Page 1 of 8
(page number not for citation purposes)
Available online http://ccforum.com/content/11/S5/S6
Abstract
Continued safety assessment is essential for any newly approved
therapy. Drotrecogin alfa (activated; DrotAA), which is approved
for use in severe sepsis, has undergone clinical trials with
corresponding safety analyses since 1995. However, the only
comprehensive review of all trials is that reported in 2003 by
Bernard and coworkers. This is an important review that focuses
on the safety profile of DrotAA in all published studies (six
randomized clinical trials and five national registry studies) and in
previously unpublished data. DrotAA treatment is associated with
an increased risk for bleeding (which in general is manageable).
Nevertheless, the available evidence shows that any adverse
effects of DrotAA are outweighed by its benefits in patients with
severe sepsis who are at high risk for death. So far, more than
9,000 patients have been enrolled in clinical trials involving
DrotAA, providing a valuable safety database. It is of note that
although DrotAA does increase the risk of bleeding, this has not
been associated with an overall increase in the rate of all severe
adverse events.
Introduction
Drotrecogin alfa (activated; DrotAA) is the first and thus far
only compound proven to improve survival in patients with
severe sepsis. The mechanisms that underlie the improved
survival are not entirely clear. A number of studies have
demonstrated that DrotAA exerts an anticoagulant effect
through inactivation of coagulation factors Va and VIIIa [1], an
anti-inflammatory effect [2] and a profibrinolytic effect [3], as
well as antiapoptotic [4] and cytoprotective effects [5]. Of
these, the anticoagulant property is the action associated
with the only known adverse effect of treatment, namely an
increased risk for bleeding.
Continued assessment of safety is essential in any newly
approved therapy. DrotAA has been studied in clinical trials
since 1995 (Table 1). It was approved for use in adult
patients with severe sepsis at high risk of death in the USA in
November 2001 [6] and in the European Union in August
2002 [7]. The European Medicines Agency indicates that
DrotAA may be used in the treatment of adult patients with
severe sepsis and multiple organ failure, and reaffirmed this
indication as a result of the second annual licence reassess-
ment, stating that DrotAA should be considered mainly in
situations in which therapy can be initiated within 24 hours
after the onset of organ failure [8].
From the very first clinical study, safety analyses have been
included in each controlled trial conducted in DrotAA, and
continuous safety surveillance has formed part of all studies
undertaken for the purposes of registering the drug for
commercial use. In this review we analyze the available
literature regarding the safety of DrotAA, together with some
previously unpublished data.
Safety profile in clinical trials
In the early phase I studies, begun more than 10 years ago,
adverse events with a frequency of 5% or greater included
headache (30.9%), ecchymosis (23.0%), and pain (5.8%),
primarily at the site of venopuncture [9]. These studies were
conducted in healthy volunteers mainly to evaluate pharmaco-
kinetics, and no further safety issues were identified to
prevent future clinical development [9]. The data regarding
serious bleeding events are summarized in Table 2. The
definition of a serious bleeding event includes any intracranial
hemorrhage, any life-threatening or fatal bleed, any bleeding
event requiring the administration of three or more units of
packed red blood cells per day for 2 consecutive days, or any
bleeding event considered serious by the investigator. A
similar definition was adopted for all DrotAA studies except
for ADDRESS and XPRESS, in which requirements for trans-
fusion were not included.
The first patients with severe sepsis to receive DrotAA were
those included in the EVAA (dose finding) study [10]. This
was a proof-of-concept study that investigated the safety
profile of DrotAA and determined the optimal dosage for
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future trials. Four (4%) patients receiving DrotAA and two
(5%) patients receiving placebo during the 28-day period of
study reported serious bleeding events. Two events,
haematemesis and worsening haematoma, occurred during
DrotAA infusion and the other two, worsening gastrointestinal
hemorrhage and hemorrhage during laparotomy, occurred 1
and 25 days after infusion. The two gastrointestinal
hemorrhages in the control group occurred 3 and 4 days after
placebo infusion.
In EVAA, overall, there was no statistically significant differ-
ence between DrotAA-treated and placebo-treated patients
experiencing at least one serious adverse event (39% versus
46%, respectively; P = 0.422). Skin rash occurred more
frequently among DrotAA-treated than placebo-treated
patients (10% versus 0%, respectively; P = 0.036). None of
the rashes was classified as serious or considered by the
investigators to be drug related. No significant differences in
specific treatment-emergent adverse events were recorded
Table 1
Drotrecogin alfa (activated) clinical trials
Study Study type/patients or treatments included Number of patients included Study period Reference
EVAA Dose-finding phase II 131 1997 to 1998 [10]
PROWESS Phase III 1,690 1998 to 2000 [11]
ENHANCE Open-label 2,378 2001 to 2003 [12]
ADDRESS Low risk for death 2,640 2002 to 2004 [13]
RESOLVE Sepsis in children 477 2002 to 2005 [24]
XPRESS Heparin + DrotAA 1,927 2003 to 2005 [14]
ADDRESS, Efficacy and Safety of Drotrecogin alfa [activated] in Adult Severe Sepsis Patients at Low Risk of Death; DrotAA, drotrecogin alfa
(activated); ENHANCE, Extended Evaluation of Recombinant Human Activated Protein C, drotrecogin alfa (activated); EVAA, [dose finding study];
PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; RESOLVE, REsearching severe Sepsis and Organ
dysfunction in children: a gLobal perspective; XPRESS, Xigris and Prophylactic Heparin Evaluation in Severe Sepsis.
Table 2
Serious adverse events including bleeding events through clinical trials 
Placebo-controlled studies Open-labela
PROWESS ADDRESS ENHANCE XPRESS
DrotAA Placebo DrotAA Placebo DrotAA DrotAA 
Adverse events (n = 850) (n = 840) (n = 1,317) (n = 1,293) (n = 2,378) (n = 1,935)
Study drug infusion period*
Serious events 58 (6.8) 55 (6.5) 75 (5.7) 78 (6.0) 166 (7.0) 128 (6.6)
Serious bleeds 20 (2.4) 8 (1.0) 31 (2.4) 15 (1.2) 85 (3.6) 46 (2.4)
CNS bleeds 2 (0.2) 0 4 (0.3) 3 (0.2) 15 (0.6) 6 (0.3)
Days 0 through 28
Serious events 106 (12.5) 102 (12.1) 182 (13.8) 183 (14.2) 319 (13.4) 256 (13.2)
Serious bleeds 30 (3.5) 17 (2.0) 51 (3.9) 28 (2.2) 155 (6.5) 88 (4.5)
CNS bleeds 2 (0.2) 1 (0.1) 6 (0.5) 5 (0.4) 35 (1.5) 17 (0.9)
*In PROWESS and ENHANCE, the study drug infusion period was defined as the actual infusion plus 1 day. In ADDRESS, RESOLVE and
XPRESS, the study drug infusion period was defined as study days 0 through 6. Values are expressed as n (%). aENHANCE was an open-label
study. XPRESS was a placebo-controlled study of the co-administration of heparin with drotrecogin alfa (activated); the drug under study was
heparin; open-label drotrecogin alfa (activated) was administered to all patients. ADDRESS, Efficacy and Safety of Drotrecogin alfa [activated] in
Adult Severe Sepsis Patients at Low Risk of Death; CNS, central nervous system; DrotAA, drotrecogin alfa (activated); ENHANCE, Extended
Evaluation of Recombinant Human Activated Protein C, drotrecogin alfa (activated); PROWESS, Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis; XPRESS, Xigris and Prophylactic Heparin Evaluation in Severe Sepsis. Modified with permission from
Williams MD, Macias W, Rustige J: Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions. Intensive Care Med
2007, 33:1487-1488. © Springer-Verlag.Page 3 of 8
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and no safety issues were identified in central laboratory
parameters or vital signs.
For 53 treated patients, samples for anti-DrotAA antibody
testing were available. A low-level anti-DrotAA antibody
response was reported in one patient; the antibodies were
non-neutralizing with respect to the anticoagulant activity.
This patient did not experience any related clinical adverse
events and was negative for anti-DrotAA antibody response
1 year after exposure.
These EVAA results were sufficiently encouraging to proceed
to the pivotal phase III double-blind, randomized, placebo-
controlled PROWESS (Recombinant Human Activated
Protein C Worldwide Evaluation in Severe Sepsis) trial.
PROWESS, ENHANCE, ADDRESS, and
XPRESS
These four studies used all the same dose of DrotAA
(24 μg/kg per hour), which was the one that was demon-
strated to be more effective and safe in EVAA.
The pivotal phase III PROWESS trial [11] included 850
DrotAA-treated and 840 placebo-treated patients. The
percentages of patients experiencing at least one serious
adverse event were 12.1% in the DrotAA group and 12.5%
in the placebo group (P = 0.84), whereas percentages of
those experiencing at least one bleeding event were 24.9%
in the DrotAA group and 17.7% in the placebo group
(P < 0.05). The majority of bleeding events in both groups
were ecchymosis or gastrointestinal tract bleeding and were
not considered serious. The difference in the incidence of
serious bleeding events between the two treatment groups
occurred primarily during drug administration.
In ENHANCE (Extended Evaluation of Recombinant Human
Activated Protein C, drotrecogin alfa [activated]), a single-arm,
open-label trial [12], a total of 2,378 adult patients with severe
sepsis received DrotAA. Given that the rate of serious  bleeding
events was also higher in ENHANCE during the post-infusion
period, where, due to the short half-life of the drug, patients
were not exposed to DrotAA, this suggests a higher baseline
risk for bleeding in ENHANCE compared with PROWESS, with
higher degrees of both haematologic and hepatic dysfunction,
both of which are associated with increased bleeding risk. The
incidences of serious bleeding events in both the infusion and
post-infusion periods in the PROWESS and ENHANCE studies
are summarized in Table 2.
The ADDRESS (Efficacy and Safety of Drotrecogin alfa
[activated] in Adult Severe Sepsis Patients at Low Risk of
Death) study [13] involved 1,317 DrotAA-treated and 1,293
placebo-treated patients. The percentages of patients
experiencing at least one bleeding event in the DrotAA and
placebo treatment groups were 10.9% and 6.4%, respec-
tively (P < 0.001). The numbers of serious bleeding events
during infusion (defined as study day 0 through to study
day 6) were 31 (2.4%) in DrotAA-treated and 15 (1.2%) in
placebo-treated patients (P = 0.02). The numbers of patients
suffering central nervous system (CNS) bleeding during
infusion were 4 (0.3%) and 3 (0.2%) in the DrotAA and
placebo groups, respectively. Recent surgery (within 30 days
before study entry) was associated with a greater risk for
serious bleeding during infusion in both the DrotAA-treated
and placebo-treated patients (3.6% versus 1.6% in DrotAA-
treated patients with and without recent surgery, respectively;
and 1.6% versus 0.9% placebo-treated patients with and
without recent surgery, respectively); however, this difference
between groups was not significant.
XPRESS (Xigris and Prophylactic Heparin Evaluation in
Severe Sepsis) [14] was an open label study, all the patients
received DrotAA and the study drug was prophylactic heparin
or placebo. It included patients with severe sepsis and
greater disease severity (for example, a higher rate of organ
dysfunctions) than in previous studies (because it was
performed in an on-label population), who were undergoing
treatment with DrotAA. Serious bleeding rates were consis-
tent with those observed in previous studies throughout the
6-day treatment period, and prophylactic heparin did not
increase the risk for serious bleeding compared with placebo
(2.3% and 2.5%, respectively), including CNS bleeding
(0.3% in both arms). However, the group receiving prophy-
lactic heparin had a significantly higher rate of nonserious
bleeding in comparison with the placebo group (8.7% versus
5.7%, respectively; P = 0.0116).
Serious bleeding events during the 28-day
study period
In PROWESS the incidence of serious bleeding events
during the 28-day study period was 3.5% in DrotAA-treated
and 2.0% in placebo-treated patients. The incidences of
CNS bleeds during this period were 0.2% and 0.1% for
DrotAA-treated and placebo-treated patients, respectively.
The risk for CNS bleeding may increase with severe coagulo-
pathy and severe thrombocytopenia [15]. In ADDRESS the
corresponding results were 3.9% in DrotAA-treated and
2.2% in placebo-treated patients (P = 0.01), and 0.5% and
0.4%, respectively, for CNS bleeds.
Serious bleeding rates in XPRESS [14] were consistent with
those observed in previous studies during the 28-day period
of study. Prophylactic heparin did not increase the risk for
serious bleeding for DrotAA compared with placebo (3.9%
versus 5.2%, respectively), including CNS bleeding (1.0%
versus 0.7%, respectively). In ENHANCE, 6.5% of DrotAA-
treated patients had serious bleeding events during days 0 to
28, and the incidence of CNS bleeds was 1.5%.
Safety profile outside controlled clinical trials
Two years after DrotAA had been approved by the US Food
and Drug Administration for use in adult patients with severe
Available online http://ccforum.com/content/11/S5/S6sepsis at high risk of death, Bernard and coworkers [16]
reported the first post-marketing safety assessment, and at
least five National Registries have been published to date
[17-21].
Although all of the referenced studies [17-21] carried out a
safety analysis, the findings are not entirely comparable
because diverse definitions of bleeding were employed in the
different registries and these were sometimes different from
those used in the controlled clinical trials. Table 3 summarizes
the registries that included safety findings.
Safety profile in special populations
Surgical patients
Surgical patients with severe sepsis account for 25% to 50%
of patients treated in randomized clinical trials and registry
studies of DrotAA. The main complication after major surgery
is bleeding, and therefore this group of patients represents a
special population from a safety standpoint. The main analysis
of treated patients published so far concluded that although
patients receiving DrotAA are at greater risk for bleeding, the
risk-benefit profile still favors use of DrotAA in patients in
whom it is indicated [22].
The PROWESS Trial Surgical Evaluation Committee on
efficacy and safety of DrotAA in surgical patients confirmed
28% of cases as surgical. Barie et al. [22], moreover, report
that for all surgical patients and those undergoing
intraabdominal procedures, the absolute risk reduction for
mortality was 3.2% and 9.1%, respectively. Administration of
DrotAA was  associated with an increased risk for serious
bleeding during the infusion period in both the overall
PROWESS patients (P = 0.024) and the surgical cohort (P =
0.006); however, the surgical patients did not demonstrate
excessive risk of bleeding compared with nonsurgical patients
who received DrotAA.  Serious bleeding during the infusion
and 28-day period was similar between surgical and
nonsurgical patients. For the three patient populations
PROWESS overall, PROWESS Surgical and PROWESS
non-Surgical, respectively, the serious bleeding event rates
were 2.4% versus 3.1% versus 2.1% during the infusion
period, and 3.5% versus 3.5% versus 3.5% during the 28-day
period. In ADDRESS, recent surgery (within 30 days prior to
study entry) was associated with a numerically higher risk of
serious bleeding during infusion in both the Xigris-treated and
the placebo-treated patients (Xigris: 3.6% in patients with
recent surgery versus 1.6% in patients without recent surgery;
placebo: 1.6% versus 0.9%, respectively).
Among the small number of patients (98) enrolled in
PROWESS with single organ dysfunction and recent surgery
(surgery within 30 days prior to study treatment), 28-day all-
cause mortality was 10/49 versus 8/49 for the Xigris and
placebo patients, respectively (*P = 0.60); the in-hospital
mortality was 14/48 versus 8/47 for the Xigris and placebo
patients, respectively (*P = 0.16). The subset of patients (636)
with single organ dysfunction and recent surgery from the
randomized, placebo-controlled study (ADDRESS) of septic
patients at lower risk of death (Acute Physiology and Chronic
Health Evaluation [APACHE] II score <25 or single sepsis-
induced organ failure at any APACHE II score) had a 28-day
all-cause mortality of 67/323 versus 44/323 for Xigris and
placebo patients, respectively (*P = 0.03) and an in-hospital
mortality of 76/325 versus 62/314 for Xigris and placebo
patients, respectively (*P = 0.26). (*Chi-square test without
adjustment for multiple comparisons.)
The incidence of serious bleeding events in patients with
single organ dysfunction and recent surgery reported in
PROWESS during infusion was 4.2% versus 0% for Xigris
and placebo patients, respectively (P = 0.16) and during the
28-day period was 4.2% versus 0% for Xigris and placebo
patients, respectively (P = 0.16); in ADDRESS the incidence
of serious bleeding events during infusion was 4.4% versus
1.9% for Xigris and placebo patients, respectively (P = 0.08),
and for 28 days 5.0% versus 2.9% for Xigris and placebo
patients, respectively (P = 0.17). 
DrotAA is not indicated for patients with single organ
dysfunction and in particular should not be used in patients
with single organ dysfunction and recent surgery. 
Recommendations for patients under interventions
When surgery or other invasive procedures are performed
during the infusion of DrotAA, the recommendations for
interruption of infusion should be followed to minimize the risk
for bleeding. Pharmacokinetic studies show that DrotAA has
a short half-life. Plasma concentrations decline rapidly, with
no measurable activity within 2 hours after the infusion is
stopped.
As stated in the current European Summary of Product
Characteristics, ‘For procedures with an inherent bleeding
risk, discontinue drotrecogin alfa (activated) for 2 hours prior
to the start of the procedure. Drotrecogin alfa (activated) may
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Table 3
Safety profile in national registries
UK Poland  Italy  Canada 
[17] [19] [20] [21]
Patients (n) 1279 302 324 261
Adverse events (%) 7.4 N/A N/A N/A
Bleeding (%) 5.9 6 9 N/A
Serious bleeding (%) N/A 1.7 4 10
Only the four published national registries in which safety analyses
were consistent or part of the objectives of the study are listed here.
Note that different definitions were used for bleeding and serious
bleeding among registries, and these were also different between
registries and controlled clinical trials. N/A = Not available.be restarted 12 hours after major invasive procedures or
surgery if adequate haemostasis has been achieved.
Drotrecogin alfa (activated) may be restarted immediately
after uncomplicated less invasive procedures if adequate
haemostasis has been achieved.’ [8].
The decision regarding the interruption/post-procedure
reinstitution of DrotAA for surgical procedures should be
made by the attending clinician on a case-by-case basis after
thorough assessment of benefit versus risk. Table 4 [23]
provides guidelines for interruption and eventual restart of
DrotAA in patients treated invasively.
Pediatric patients
DrotAA is not recommended for use in persons under the age
of 18 years and should not therefore be used in these
patients. From a safety point of view, in the RESOLVE
(REsearching severe Sepsis and Organ dysfunction in
Available online http://ccforum.com/content/11/S5/S6
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Table 4
Guidelines for interrupting drotrecogin alfa (activated) infusion for an invasive procedure 
Procedurea Pre-procedure: stop DrotAA Post-procedure: reconsider DrotAAb
Minor procedure 
Arterial line insertion  2 hours before procedure Immediately afterward
Venous femoral line insertion 2 hours before procedure Immediately afterward
Re-intubation (tube change) 2 hours before procedure Immediately afterward
More invasive procedure
Central venous catheter insertion via  2 hours before procedure Immediately afterward
compressible site (e.g. via femoral vein)
Central venous catheter insertion via  2 hours before procedure 2 hours afterward
noncompressible site (e.g. via subclavian or 
jugular vein)
Chest tube insertion or thoracic drainage 2 hours before procedure 2 hours afterward
Gastroscopy (possible biopsy) 2 hours before procedure 2 hours afterward
Lumbar puncture 2 hours before procedure 2 hours afterward
Nephrostomy 2 hours before procedure 2 hours afterward
Paracentesis 2 hours before procedure 2 hours afterward
Percutaneous drainage 2 hours before procedure 2 hours afterward
Sinus puncture 2 hours before procedure 2 hours afterward
Tracheostomy 2 hours before procedure 1 hour afterward
Wound debridement (decubitus ulcer,  2 hours before procedure 2 hours afterward
infected wound, packing changes in open 
abdomen, etc.)
Major procedure
Major surgical procedurec 2 hours before procedure Wait 12 hours
Epidural catheter 2 hours before procedure; withhold drotrecogin  Wait at least 12 hours after catheter 
alfa (activated) while catheter present removal before initiating drotrecogin alfa 
(activated) infusion
Other
CPR When beginning CPR Evaluate neurologic status before resuming 
drotrecogin alfa (activated). If chest trauma occurred, 
wait 12 hours
aThese guidelines assume that the procedures listed (with the exception of initiation of cardiopulmonary resuscitation [CPR]) are non-emergency.
For emergency procedures, the drotrecogin alfa (activated; DrotAA) infusion should be discontinued as soon as possible. The subsequent decision
regarding whether and when to reinitiate the infusion depends on the type of procedure and the patient’s clinical condition. bIf no signs and
symptoms of bleeding are present and the investigator/clinician feels that there is minimal risk for bleeding complications. cA significant surgical
procedure that requires the use of an operating room, anesthesia, and so on. DrotAA, drotrecogin alfa (activated). Modified with permission from
Laterre and Wittebole [23].children: a gLobal perspective) study [24], a double-blind,
placebo-controlled trial conducted in children with severe
sepsis, the investigators attributed two deaths in the DrotAA
group and five in the placebo group to bleeding events. There
was a higher rate of CNS bleeding in the DrotAA group than
in the placebo group. Over the infusion period (study days 0
to 6), the number of patients experiencing CNS bleeding was
5 (2.1%) in the DrotAA group compared with 1 (0.4%) in the
placebo group, with four of the five events in the DrotAA
group occurring in children aged 60 days or younger, or with
a body weight of 3.5 kg or less. Fatal CNS bleeding events,
serious bleeding events (over the infusion period and over the
28-day study period), serious adverse events, and amputa-
tions were similar in the DrotAA and placebo groups.
Interaction with other drugs
In the XPRESS trial [14] a total of 1,935 adult patients with
severe sepsis treated with DrotAA were randomly assigned
to receive either prophylactic heparin or placebo. Prophy-
lactic heparin doses used in XPRESS were 10,000 U/day
unfractionated heparin or 40 mg/day enoxaparin administered
subcutaneously. The subgroup of patients whose baseline
heparin was discontinued at randomization exhibited
increased mortality and serious adverse events, including
cardiac, gastrointestinal, and venous thrombotic events.
Therefore, prophylactic heparin should not be discontinued
before initiating treatment or during treatment with DrotAA,
unless it is considered medically necessary for other reasons.
Starting treatment with DrotAA does not in itself require
cessation of prophylactic heparin.
In 2004, Mann and coworkers [25] reported an observation on
the compatibility of DrotAA with 34 other very commonly used
therapies when infused through a ‘Y’ site infusion device. Of the
34 test drugs, eight were defined as visually compatible with
DrotAA.
Immunogenicity and re-administration
In patients with severe sepsis, the formation of anti-DrotAA
antibodies was uncommon (<1%) after a single course of
therapy. These antibodies were not capable of neutralizing the
effect of activated protein C in the activated partial thrombo-
plastin time assay. However, the possibility of allergic reactions
to constituents of the preparation cannot be completely
excluded in certain predisposed patients 8]. sick individuals,
even after repeated administration. DrotAA re-administration is
not contraindicated 8]; a few anecdotal reports describe
repeated re-administration in a clinical setting [26].
Discussion
Clinical trials with DrotAA have now been performed for
longer than 10 years and all have shown the same pattern in
terms of safety. DrotAA increases the risk for bleeding
without increasing general adverse events, thus resulting in
similar rates of serious adverse events in treated arms
compared with placebo.
Other types of adverse events (risk for superinfection,
formation of blocking antibodies) were prospectively
measured in randomized controlled trials and the results were
consistent across trials. The only adverse event attributable to
DrotAA is an increased risk for bleeding. Serious adverse
bleeding events in randomized trials occurred at consistently
low rates, as shown in Table 2.
The increase in the number of bleeding events compared with
placebo can be explained given the mechanism of action of
DrotAA. The risk for bleeding can be reduced by following
simple guidelines and avoiding off-label use (use in contra-
indicated patients). It is important to note that the intracranial
hemorrhage rate in all of the studies is in accordance with the
rate of spontaneous intracranial hemorrhage in critically ill
patients [27]. Moreover, some studies have suggested that
the rate of intracranial hemorrhage may be much higher in
patients with septic shock. In one study, autopsy examination
revealed evidence of cerebral hemorrhage in six out of 23
septic shock patients (26%) [15].
In other settings, such as acute cardiac syndrome, the use of
thrombolytic or antiplatelet compounds carry an inherent risk
for bleeding that is even greater than that observed with
DrotAA, but nevertheless this risk is considered acceptable.
It has been postulated that the anticoagulant effect of DrotAA
may play a less important role in increasing survival rate in
severe sepsis patients at high risk for death. Hence,
development of a new form of the therapy with a reduced
anticoagulant effect, while conserving its other properties,
might enhance the benefit-risk ratio [28]. Nevertheless, when
comparing the risk for bleeding in DrotAA-treated patients
with the risk in those enrolled in trials of other natural
anticoagulants, the benefit-risk ratio is greater in DrotAA
patients [29,30].
A recently published long-term follow up of ADDRESS [31]
concluded that DrotAA exerts no harmful effects in patients
with severe sepsis who are at low risk for death. Also,
because of the drug’s pharmacokinetic characteristics, any
such effects would be limited to the infusion period, whereas
its benefits persist in the population for which it is indicated.
Numerous registries have been reported to date. The
conclusions of all of these studies recognize that DrotAA is
the only compound to have demonstrated any effect on
survival in septic patients and that there is no evidence that
risk outweighs benefit when it used within the indicated
population [32]. Efforts should be focused on education and
adequate patient identification [21], especially in the setting
of sepsis, where abnormal coagulation is the rule [33].
Conclusion
Although DrotAA increases the risk for bleeding, the safety
profile remains acceptable for the indicated population after
Critical Care    Vol 11 Suppl 5 Fumagalli and Mignini
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benefit to patients at high risk for death is not outweighed by
the adverse effects of DrotAA [34]. The increased risk for
bleeding can be minimized by following simple guidelines and
through appropriate patient selection.
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